The goal of this study is to assess the safety and preliminary anti-cancer activity of an oncolytic virus administered as an intravenous injection or intravenous and intratumoral injections (if tumors are in locations amenable to injection) Oncolytic viruses are genetically modified to directly destroy cancer cells and recruit immune cells to assist with the anti-cancer effect. In addition, the genetic modification makes these products non-virulent to normal cells.
The study duration is 4 weeks per dog. Enrolled dogs will receive up to 4 weekly treatments during this time. There is no placebo group in this study, which means all dogs receive the oncolytic virus.
Trained veterinarians at the trial sites will evaluate each dog for eligibility.
- Confirmed diagnosis of osteosarcoma, melanoma, soft tissue sarcoma, transitional cell carcinoma, or squamous cell carcinoma.
- At least 1 year old.
- Weighs more than 11 pounds.
- At least one measurable lesion greater than 2 cm.
- Dogs has not received anti-cancer therapy within 3 weeks of enrollment.
- Prior surgery to remove mass(es) is permitted so long as the procedure was performed at least 14 days prior to enrollment and measurable disease remains.
- Prior use of NSAIDs are permitted provided the dog has been receiving the current regimen for at least 30 days prior to enrollment.
- No other major medical problems.
- Has not received routine vaccinations within 14 days prior to enrollment.
*Other study criteria may apply. The veterinary investigator will determine eligibility at the time of consultation.*
If dogs are enrolled, the following funding is provided:
- Screening tests required by the study
- Oncolytic virus including administration costs
- Study-related exams and diagnostics (e.g. Bloodwork, radiographs “x-rays”, abdominal ultrasound).
- Side effects if attributable to the oncolytic virus